Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will participate in four national benefits conferences throughout June to present its artificial intelligence-powered cardiovascular risk assessment solutions to employers, brokers, union trustees, and plan administrators. The company aims to address the growing burden of cardiovascular disease, which remains a leading driver of health plan costs and workforce productivity losses.
The company will showcase its suite of AI-powered offerings, including Epi+Gen CHD(TM), PrecisionCHD(TM), and the HeartRisk(TM) population insights platform. These tools are designed to identify individuals at risk for cardiovascular disease earlier, enabling benefits decision-makers to implement preventive strategies that can manage healthcare costs and improve patient outcomes. According to the press release, the company’s technology leverages a proprietary Artificial Intelligence-driven Integrated Genetic-Epigenetic Engine to provide personalized risk assessments.
Cardiovascular disease is a significant financial burden for employers and health plans. By identifying at-risk individuals before a major cardiac event occurs, Cardio Diagnostics' solutions could help reduce expensive emergency interventions and long-term treatment costs. The company’s presence at these conferences underscores a growing trend among benefits professionals to adopt precision medicine approaches for population health management.
The full press release can be accessed at https://ibn.fm/qFRHu. Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company focused on making prevention, detection, and management of cardiovascular disease more accessible and personalized. The company was formed to develop and commercialize clinical tests based on its Core Technology, aiming to become a leading medical technology firm in cardiovascular care.
For more information about Cardio Diagnostics and its latest updates, visit the company’s newsroom at https://ibn.fm/CDIO. The company’s forward-looking statements are subject to risks and uncertainties as outlined in its filings with the Securities and Exchange Commission.
